In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS sells 15% of Mead through IPO that nets $684mm

Executive Summary

Keeping up with plans to limit resources on its non-pharmaceutical assets, Bristol-Myers Squibb has sold about 15% of Mead Johnson Nutrition in an IPO. BMS netted $684mm from 30mm Mead shares at $24 each, the high end of the $21-24 anticipated range. In early February it had planned to offer 25mm shares.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Financing
    • IPO
    • Spin-Off

Related Companies